44. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
作者: Nicholas A Marston.;Erin A Bohula.;Ajay K Bhatia.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Jeong-Gun Park.;Sabina A Murphy.;Emileigh Walsh.;Lyrica Liu.;Subodh Verma.;Naveed Sattar.;Stephen J Nicholls.;Jose Lopez-Sendon.;Ioanna Gouni-Berthold.;Lale Tokgozoglu.;Ron Blankstein.;Marcoli Cyrille.;Gabriel Paiva da Silva Lima.;Robert P Giugliano.;Marc S Sabatine.; .
来源: JAMA. 2026年
Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis.
|